Clinical Implications of Serum LDH，CysC，and PWR Level Detection in Lung Cancer Patients

Ying WANG; Cong FU; Ying FU

doi:10.12259/j.issn.2095-610X.S20240424

Volume 45 Issue 4

Apr. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(4): 163-169

Ying WANG, Cong FU, Ying FU. Clinical Implications of Serum LDH，CysC，and PWR Level Detection in Lung Cancer Patients[J]. Journal of Kunming Medical University, 2024, 45(4): 163-169. doi: 10.12259/j.issn.2095-610X.S20240424

Citation:

Ying WANG, Cong FU, Ying FU. Clinical Implications of Serum LDH，CysC，and PWR Level Detection in Lung Cancer Patients[J]. Journal of Kunming Medical University, 2024, 45(4): 163-169. doi: 10.12259/j.issn.2095-610X.S20240424

Citation:

PDF( 675 KB)

Clinical Implications of Serum LDH，CysC，and PWR Level Detection in Lung Cancer Patients

doi: 10.12259/j.issn.2095-610X.S20240424

Dept. of Medical Record Statistics，The 4th People’s Hospital of Changzhou City，Changzhou Jiangsu 213000，China

Received Date: 2023-12-28
Publish Date: 2024-04-25

Abstract

Abstract

Objective To investigate the clinical implications of lung function index, serum lactate dehydrogenase（LDH）, cysteine protease inhibitor C（CysC） and platelet/white blood cell ratio（PWR） in patients with lung cancer. Methods From January 2023 to June 2023, 72 patients with lung cancer in the Fourth People's Hospital of Changzhou were selected as the observation group, and 72 patients with benign lung diseases during the same period were selected as the control group. LDH, CysC, PWR and tumor markers [carcinoembryonic antigen（CEA）, neuron-specific enolase（NSE）, cytokeratin fragment 19（CYFRA21-1）] were compared between the two groups, and the correlation between LDH, PWR, CysC and tumor markers was analyzed. The levels of LDH, CysC and PWR in patients with lung cancer with different pathological characteristics were compared, and the correlation between the levels of LDH, PWR, CysC and pathological characteristics in patients with lung cancer was analyzed. The diagnostic value of LDH, CysC, PWR combined with CEA, CYFRA21-1 and NSE in lung cancer was evaluated. Results The PWR of the observation group was lower than that of the control group, and the LDH, CysC, CEA, CYFRA21-1 and NSE were higher than those of the control group（P < 0.05）. PWR was negatively correlated with tumor markers CEA, CYFRA21-1 and NSE（ P < 0.05）, LDH and CysC were positively correlated with tumor markers CEA, CYFRA21-1 and NSE（ P < 0.05）. There was no significant difference in LDH, CysC and PWR between lung adenocarcinoma and lung squamous cell carcinoma（ P > 0.05）. In terms of clinical stage, PWR of stage Ⅰ- Ⅱ patients was higher than that of stage Ⅲ-Ⅳ patients, LDH and CysC were lower than those of stage Ⅲ-Ⅳ patients（ P < 0.05）. In terms of lymph node metastasis, the PWR of patients without lymph node metastasis was higher than that of patients with lymph node metastasis, and LDH and CysC were lower than those of patients with lymph node metastasis（ P < 0.05）. LDH, PWR and CysC in lung cancer patients were not correlated with pathological type（ P > 0.05）, PWR was negatively correlated with clinical stage and lymph node metastasis（ P < 0.05）, LDH and CysC were positively correlated with clinical stage and lymph node metastasis（ P < 0.05）. The ROC curve showed that the area under the curve（AUC） value of the combination of LDH, CysC and PWR in the diagnosis of lung cancer was 0.910, and the AUC value of the combination of CEA, CYFRA21-1 and NSE was 0.923. Further use of LDH, CysC, PWR combined with CEA, CYFRA21-1, NSE diagnostic AUC value was the highest, 0.940, the sensitivity and specificity were 93.06% and 87.33%, respectively. Conclusion The PWR of lung cancer patients is decreased, and the levels of LDH and CysC are increased, and their levels are closely related to tumor markers, clinical stage and lymph node metastasis, which can assist tumor markers in the diagnosis of lung cancer, in order to improve the diagnosis rate of early lung cancer.
- Lung cancer,
- Lactate dehydrogenase,
- Cysteine protease inhibitor C,
- Platelet/leukocyte ratio

FullText(HTML)

References(23)

References

[1]	Thai A A,Solomon B J,Sequist L V,et al. Lung cancer[J]. Lancet,2021,398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3
[2]	Nooreldeen R,Bach H. Current and future development in lung cancer diagnosis[J]. Int J Mol Sci,2021,22(16):8661. doi: 10.3390/ijms22168661
[3]	Oliver A L. Lung cancer: Epidemiology and screening[J]. Surg Clin North Am,2022,102(3):335-344. doi: 10.1016/j.suc.2021.12.001
[4]	夏进,陈培,官和立,等. 早期肺癌筛查人群患病风险队列研究[J]. 现代预防医学,2023,50(12):2284-2288.
[5]	胡明明,阳苑,张同梅,等. 7843例原发肺恶性肿瘤流行病学特征分析[J]. 现代肿瘤医学,2021,29(4):682-685. doi: 10.3969/j.issn.1672-4992.2021.04.031
[6]	Liam C K,Lee P,Yu CJ,et al. The diagnosis of lung cancer in the era of interventional pulmonology[J]. Int J Tuberc Lung Dis,2021,25(1):6-15. doi: 10.5588/ijtld.20.0588
[7]	支修益,石远凯,于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志,2015,37(1):67-78. doi: 10.3760/cma.j.issn.0253-3766.2015.01.014
[8]	王敏,王媛,孙静,等. 人参养荣汤对Lewis肺癌糖酵解途径相关酶LDH-A、HK2基因表达的影响[J]. 辽宁中医杂志,2022,49(1):180-184.
[9]	刘浩,刘文,向辉,等. 半胱氨酸蛋白酶抑制剂C对胃癌侵袭与转移的影响[J]. 吉林医学,2022,43(12):3194-3197. doi: 10.3969/j.issn.1004-0412.2022.12.007
[10]	李白坤,朱继民,李庆林. 血小板与白细胞相互作用介导的肿瘤炎症微环境及其中医药治疗策略[J]. 安徽中医药大学学报,2021,40(1):93-96. doi: 10.3969/j.issn.2095-7246.2021.01.023
[11]	An J,Gu Q H,Cao L M,et al. Serum IL-6 as a vital predictor of severe lung cancer[J]. Ann Palliat Med,2021,10(1):202-209. doi: 10.21037/apm-20-2229
[12]	Yu J Q,Du F,Yang LP,et al. Identification of potential serum biomarkers for simultaneously classifying lung adenocarcinoma,squamous cell carcinoma and small cell carcinoma[J]. Cancer Biomark,2021,30(3):331-342. doi: 10.3233/CBM-201440
[13]	Xu C H,Li L,Wang W,et al. Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer[J]. J Cell Mol Med,2021,25(6):3169-3172. doi: 10.1111/jcmm.16360
[14]	Kerr K M,Bibeau F,Thunnissen E,et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe[J]. Lung Cancer,2021,154(11):161-175.
[15]	齐艳春,陈玲玲,全勍,等. ProGRP、CEA、NSE、CYFRA21-1、CA125、SCC对不同病理类型肺癌的诊断价值及联合检测的临床意义[J]. 牡丹江医学院学报,2023,44(3):62-66.
[16]	王妮娜,李晓花,陈敏丽,等. 肺癌患者血清NSE,SCC,CA125及CYFRA21-1水平检测在不同病理类型早期诊断和化疗疗效评价中的应用价值[J]. 现代检验医学杂志,2021,36(1):33-37. doi: 10.3969/j.issn.1671-7414.2021.01.009
[17]	陈礼昌,滕凤猛. 血清肿瘤标志物在肺癌不同病理分型中的应用价值[J]. 临床误诊误治,2022,35(1):29-32,47. doi: 10.3969/j.issn.1002-3429.2022.01.008
[18]	Qiu X,Shi Z,Tong F,et al. Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer[J]. Hum Vaccin Immunother,2023,19(1):2178791. doi: 10.1080/21645515.2023.2178791
[19]	Lahoud R M,O'Shea A,El-Mouhayyar C,et al. Tumour markers and their utility in imaging of abdominal and pelvic malignancies[J]. Clin Radiol,2021,76(2):99-107. doi: 10.1016/j.crad.2020.07.033
[20]	王云,牛华,方浩徽. C反应蛋白/清蛋白比率乳酸脱氢酶预测非小细胞肺癌患者预后的应用价值[J]. 安徽医学,2022,43(8):912-917. doi: 10.3969/j.issn.1000-0399.2022.08.009
[21]	李冰. 恶性肿瘤血清同型半胱氨酸和胱抑素C检测的临床价值探讨[J]. 中国疗养医学,2015,24(11):1188-1189.
[22]	Winther-Larsen A,Aggerholm-Pedersen N,Sandfeld-Paulsen B. Inflammation scores as prognostic biomarkers in small cell lung cancer: A systematic review and meta-analysis[J]. Syst Rev,2021,10(1):40. doi: 10.1186/s13643-021-01585-w
[23]	高心怡,陈丽,甘建和. MELD评分联合血小板/白细胞比值对HBV相关慢加急性肝衰竭患者预后的预测价值[J]. 临床肝胆病杂志,2021,37(5):1070-1074. doi: 10.3969/j.issn.1001-5256.2021.05.019

Relative Articles(20)

Relative Articles

[1]	Ruicheng LI, Hongwei QIAN, Yanni FAN, Peipei ZHAO, Shan WEI, Huarong JING. Application of Logistic Regression and Artificial Neural Networks in the Differential Diagnosis of LC-MPE. Journal of Kunming Medical University, 2024, 45(10): 55-60. doi: 10.12259/j.issn.2095-610X.S20241009
[2]	Qun HUANG, Lili HOU, Degui WANG, Zhaojun WANG, Siyuan WU, Yingying SANG. The Effect of Active Circulatory Breathing Training in Patients undergoing Lung Cancer Surgery under 5A Mode. Journal of Kunming Medical University, 2024, 45(6): 190-196. doi: 10.12259/j.issn.2095-610X.S20240627
[3]	Hongbo ZHANG, Zhenlong LI, Ying LV, Yichao ZHANG, Xiangming QIU, Tingting HUANG. Comparison of Clinical Efficacy of Single-port and Double-port Video-assisted Thoracoscopic Lobectomy in the Treatment of Lung Cancer. Journal of Kunming Medical University, 2024, 45(4): 135-139. doi: 10.12259/j.issn.2095-610X.S20240419
[4]	Qianrong YANG, Xue CAO, Jiao YANG, Yanqiu ZHAO, Nan SHEN, Ya Jiao SUN. Status and Influencing Factors of Stigma in Lung Cancer Patients. Journal of Kunming Medical University, 2024, 46(): 1-8.
[5]	Jiang ZHANG, Xijuan ZHAO, Jiang WU, Bingkun YANG, Ni YANG, Liping ZHOU. Analysis of Frailty Status and Influencing Factors in Lung Cancer Patients Undergoing Radiotherapy. Journal of Kunming Medical University, 2024, 45(9): 1-8.
[6]	Yajie SAI, Lvxin YAO, Ling CHENG, Li SHEN, Cailian QI, Zhaoxia WANG, Huatao NIU. Correlation Analysis between the Caregiver Burden and Life Meaning in Patients with the Early Diagnosis of Lung Cancer. Journal of Kunming Medical University, 2023, 44(9): 171-175. doi: 10.12259/j.issn.2095-610X.S20230906
[7]	Teng-fei ZHANG, Yue-feng HE, Lei ZHANG, Li ZHANG, Kai-yun YANG, Lian-qing LIU, Hui TAN. Expression of Long Non-coding RNA APTR，HEIH，FAS-ASA1，FAM83H-AS1，DICER1-AS1，PR-lncRNA in Lung Cancer. Journal of Kunming Medical University, 2021, 42(4): 49-52. doi: 10.12259/j.issn.2095-610X.S20210409
[8]	Chang LIU, Zhen-hua LI, Ying WANG, Yan-qin RUAN, Lai-hao QU, Ding-biao LI. Applications of Lung Cancer MDT Combined with PBL + CBL Model in the Clinical Teaching. Journal of Kunming Medical University, 2021, 42(9): 162-166. doi: 10.12259/j.issn.2095-610X.S20210911
[9]	Jiang ZHANG, Xi-juan ZHAO, Jiang WU, Yan LIU, Li-juan LI, Ye CHEN. Application of Family Empowerment Nursing Intervention Program in Patients with Lung Cancer Undergoing Radiotherapy. Journal of Kunming Medical University, 2021, 42(12): 169-176. doi: 10.12259/j.issn.2095-610X.S20211242
[10]	Ming-jie NING, Ying CHEN. Research Progress of The Correlation between Lung Microbiome and Lung Cancer. Journal of Kunming Medical University, 2021, 42(3): 155-160. doi: 10.12259/j.issn.2095-610X.S20210336
[11]	Li Meng Xian , Yu Jian Kun , Wen Yan Ping , Wu Han Xin , Gao Ling , Liu Xiao Xiao , Tai Wen Lin . . Journal of Kunming Medical University, 2020, 41(04): 51-55.
[12]	Zhao Min , Bi Jun Qiang , Zhou Yong Chun , Zhang Jin Ping , Luo Lei . Characteristics and Trends of Disease Constitution of 9553 Inpatients with Lung Cancer in Yunnan Province. Journal of Kunming Medical University, 2017, 38(04): 63-67.
[13]	Fan Min Juan , Zhong Yun Hua , Shen Wen , Yuan Kai Fen , Zhao Guo Hou , Wang Shu Kun , Wen Lin Qiao . HSF2 Promotes Heat Shock Protein Expression in Lung Cancer. Journal of Kunming Medical University, 2017, 38(06): 108-112.
[14]	Zhao Jie . The Expression and Significance of Galectin-3 in COPD and Lung Cancer. Journal of Kunming Medical University,
[15]	Wang Hong . Role of Prostaglandin E2 in the Pathogenesis of COPD with Lung Cancer. Journal of Kunming Medical University,
[16]	Liu Yu . The Value of Renal Tubular Injury Biomarkers in Diagnosis of Primary Nephrotic Syndrome. Journal of Kunming Medical University,
[17]	He Xiao Yu . . Journal of Kunming Medical University,
[18]	Pan Long Fang . . Journal of Kunming Medical University,
[19]	Chen Jin Run . . Journal of Kunming Medical University,
[20]	Ma Jian Qiang . . Journal of Kunming Medical University,